Sangamo Adds To Its Own Gene Therapy Technology With Ceregene Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech will bolster its own internal programs, as well as gain a potentially lucrative mid-stage asset through the acquisition, with no effect on its own balance sheet.